From the Research
Tauroursodeoxycholic acid (TUDCA) may be beneficial for patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, with a potential dosage of 1000 mg/day or higher, as it has been shown to reduce the risk of death and improve survival in these patients. The use of TUDCA in neurodegenerative diseases is supported by its anti-apoptotic and neuroprotective activities, as well as its ability to reduce oxidative stress and inflammation 1. In patients with ALS, TUDCA has been shown to improve survival and reduce the risk of death, particularly when used at higher dosages 2. The TUDCA-ALS trial, a phase III randomized controlled trial, is currently investigating the efficacy and safety of TUDCA as an add-on treatment to riluzole in patients with ALS 3, 4. While the results of this trial are pending, the available evidence suggests that TUDCA may be a promising treatment option for patients with ALS and other neurodegenerative diseases.
Some key points to consider when using TUDCA include:
- The typical recommended dosage ranges from 250-1500 mg daily, taken with meals for better absorption
- Higher dosages (1000 mg/day or higher) may be more effective in reducing the risk of death and improving survival in patients with ALS
- TUDCA may be beneficial for patients with other neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease
- TUDCA should not replace medical treatment for neurodegenerative diseases, and patients should consult with a healthcare provider before starting supplementation, especially if they have existing health conditions or are taking medications
- Side effects are generally mild but may include digestive discomfort, and TUDCA is generally well-tolerated 2.
Overall, the available evidence suggests that TUDCA may be a useful treatment option for patients with neurodegenerative diseases, particularly ALS, and further research is needed to fully understand its potential benefits and risks.